Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Israel faces tough choices over haredi draft exemptions, legal expert warns - 2From Overpowered to Coordinated: Individual Accounts of Cleaning up
- 3Denny's is shutting down restaurants around the country. What's behind the closures?
- 4Top 10 Arising Advances That Will Shape What's in store
- 5The Most Notable Design Brands of the 21st Hundred years
- Who plays Moana in the live-action remake? What to know about Catherine Lagaʻaia.
- How much would you pay to meet a Real Housewife? At BravoCon, the limit does not exist.
- Joshua Made Last-Second Seat Change That Saved His Life
- Antivirus Programming for Exhaustive Security
- 6 Eyewear Brands Worth Purchasing
- Step by step instructions to Involve Compact disc Rates for Magnanimous Giving
- Instructions to Investigate Different Open Record Extra Offers Actually
- How comfort foods trigger pleasure in our brains
- Israel's haredi draft crisis: Court ruling and political stalemate reach breaking point
